Text Size

ECLAXIR:Search for an Association Between CX3CR1 V249I Polymorphism, Preeclampsia and Endothelial Injury

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT00190177
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The study hypothesis is the involvement of the couple CX3CR1/CX3CL1 in occurrence of endothelial injury in preeclampsia. According to this hypothesis, Carriers of the I249 allele who express less CX3CR1 shoud be protected against this risk. The main objective of the study is the search of an association between CX3CR1 V249I polymorphism and preeclampsia. The secondary aims are the search of an association with the most severe forms of preeclampsia and endothelial injury.


Condition
Preeclampsia

Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Retrospective

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Estimated Enrollment: 370
Detailed Description:

It is a case-control multicenter study 185 caucasian pregnant women with preeclampsia and 185 paired controls without preeclampsia will be included.

The frequency of the V249I polymorphism in african black population will be determined by studying 200 subjects (100 cases and 100 controls).

The V249I polymorphism will be identified by PCR followed by enzyme digestion. Endothelial injury will be identified using three assays : von Willebrand factor, soluble VCAM-1 and thrombomodulin plasma levels.

CX3CR1 involvement in preeclampsia would have potential diagnostic and therapeutic consequences.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • cases: pregnant woman, evolutive pregnancy, preeclampsia, caucasian, consenting to the study

Exclusion Criteria:

  • Cases:

multiple pregnancy, proteinuria > 300 mg/24h before 21th gestation week.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00190177

Contacts
Contact: Dominique de Prost dominique.de-prost@lmr.aphp.fr

Locations
France
Hôpital Louis Mourier AP-HP Recruiting
Colombes, France, 92701
Contact: Dominique de Prost, MD-PhD         dominique.de-prost@lmr.aphp.fr    
Principal Investigator: Laurent Mandelbrot, MD-PhD            
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Laurent Mandelbrot, MD-PhD AP-HP
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00190177     History of Changes
Other Study ID Numbers: P020925
Study First Received: September 12, 2005
Last Updated: September 12, 2005
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on June 17, 2013